Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




RF Ablation Successful in Treating Inoperable Lung Cancer

By HospiMedica staff writers
Posted on 09 Apr 2007
A minimally invasive procedure known as radiofrequency (RF) ablation is effective for treating lung cancer in patients who are not candidates for surgery, according to a recent study.

Damian Dupuy, M.D., director of ablation at Rhode Island Hospital (Providence, RI, USA) and professor of diagnostic imaging at the Warren Alpert Medical School of Brown University (Providence, RI, USA), conducted a study of 153 patients who were treated for early-stage, inoperable lung cancer with RF ablation. More...
The procedure involves using a specialized needle inserted through the skin to transmit high-frequency electrical currents into a tumor.

The overall findings of the study revealed RF ablation safe and tied it to promising long-term survival and local tumor progression outcomes when compared to the older treatment method of external beam radiation (EBT).
EBT, which has been used for decades, requires many treatments over a six-week period. This can frequently lead to a variety of side effects. RF ablation, however, is performed in a single day on an outpatient basis, is minimally invasive and has few side effects.

"Our study has shown that this minimally invasive procedure can successfully treat patients with lung cancer who could not undergo surgery in one fairly simple treatment. The study also shows that radiofrequency ablation is equal to or more effective in terms of both survival and tumor control,” commented Dr. Dupuy. With RF ablation, the Rhode Island Hospital researchers noted a two-year survival rate at 57% compared to 51% using EBT.
"With lung cancer screening for at-risk individuals on the horizon, we will be able to detect lung cancers at earlier stages. In my lifetime, I foresee image-guided radiofrequency ablation replacing many surgical procedures for the treatment of cancer as we continue to improve these minimally invasive treatment methods,” stated Dr. Dupuy.

Other survival rates for stage I, non-small cell cancer treated with RF ablation were 78% for one year, 57% for two years, 36% for three years, and 27% for both four and five years.

The study was published in the April 2007 issue of the journal Radiology.


Related Links:
Brown University

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.